Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2010. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding an increase in their holdings of Ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The only financial figure disclosed is the transaction price of £12.99 per Ordinary share.
Material Changes
The material change reported is an increase in share interests for specific individuals following the re-investment of dividends paid to shareholders on January 7, 2010. The specific increases in share counts are as follows:
- Mr A P Witty: 513 shares
- Mrs C M Witty: 397 shares
- Mr J S Heslop: 208 shares
- Mr D Learmouth: 171 shares
- Dr D Pulman: 180 shares
- Mrs C R Pulman: 60 shares
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risks, contingencies, or unusual items. It is strictly a regulatory disclosure of director share transactions in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the dividend reinvestment date of January 7, 2010, and the corresponding share price of £12.99.
- Confirm the updated total shareholdings for the named directors and connected persons.
- Note that this filing does not contain operational or financial performance data for the company.